| Note | 2023 | 2022 (restated)* | |
|---|---|---|---|
| Cash flows from operating activities | |||
| Profit before tax | 8,562 | 4,767 | |
| Income tax paid | (1,793) | (1,429) | |
| Total adjustments: | 40,108 | 15,205 | |
| Depreciation and amortization | 27, 18 | 1,371 | 1,267 |
| (Gains)/losses on investing activities | 71 | (87) | (97) |
| Interest and dividends received | 71 | (6,549) | (3,758) |
| Interest paid | 71 | 754 | 581 |
| Change in: | |||
| amounts due from banks | 71 | (905) | (213) |
| hedging derivatives | (4,609) | 2,554 | |
| other derivative instruments | 1,069 | (289) | |
| securities | 71 | (6,360) | (4,288) |
| loans and advances to customers | 71 | (13,282) | 1,686 |
| reverse repo transactions | (365) | (7) | |
| assets in respect of insurance activities | 24 | 13 | |
| property, plant and equipment under operating lease | (353) | (640) | |
| non-current assets held for sale | 71 | (8) | 8 |
| other assets | 71 | 360 | (216) |
| accumulated allowances for expected credit losses | 71 | 381 | 1,191 |
| accumulated allowances on non-financial assets and other provisions | 71 | 2,222 | 270 |
| amounts due to the Central Bank | 1 | 1 | |
| amounts due to banks | 412 | (810) | |
| amounts due to customers | 60,325 | 17,602 | |
| liabilities in respect of insurance activities | 37 | (439) | |
| loan and advances received | 71 | 335 | (35) |
| liabilities in respect of debt securities in issue | 71 | (500) | 742 |
| subordinated liabilities | 71 | (7) | 65 |
| other liabilities | 71 | 2,662 | 1,905 |
| Other adjustments | 71 | 3,180 | (1,888) |
| Net cash from/used in operating activities | 46,877 | 18,543 |
* The Statement of cash flows for 2022 was restated due to the implementation of IFRS 17 “Insurance Contracts” (see note “IFRS 17 Insurance Contracts”).
| Note | 2023 | 2022 (restated)* | |
|---|---|---|---|
| Cash flows from investing activities | |||
| Inflows from investing activities | 788,046 | 102,154 | |
| Redemption of securities measured at fair value through other comprehensive income | 774,906 | 89,661 | |
| Redemption of securities measured at amortized cost | 6,371 | 7,765 | |
| Interest received on securities measured at fair value through other comprehensive income | 4,396 | 1,987 | |
| Interest received on securities measured at amortized cost | 2,139 | 1,720 | |
| Proceeds from disposal of intangible assets, property, plant and equipment and assets held for sale | 142 | 255 | |
| Other inflows from investing activities including dividends | 71 | 92 | 766 |
| Outflows on investing activities | (835,624) | (97,116) | |
| Increase in equity of joint ventures | – | – | |
| Purchase of securities measured at fair value through other comprehensive income | (810,745) | (92,919) | |
| Purchase of securities measured at amortized cost | (23,111) | (2,452) | |
| Purchase of intangible assets and property, plant and equipment | (1,768) | (1,038) | |
| Other outflows on investing activities | 71 | – | (707) |
| Net cash from/used in investing activities | (47,578) | 5,038 |
* The Statement of cash flows for 2022 was restated due to the implementation of IFRS 17 “Insurance Contracts” (see note “IFRS 17 Insurance Contracts”).
| Note | 2023 | 2022 (restated)* | |
|---|---|---|---|
| Cash flows from financing activities | |||
| Payment of dividends | – | (2,288) | |
| Proceeds from debt securities in issue | 71 | 13,105 | 8,421 |
| Redemption of debt securities | 71 | (10,914) | (17,525) |
| Taking up loans and advances | 71 | 12 | 620 |
| Repayment of loans and advances | 71 | (1,152) | (753) |
| Payment of lease liabilities | 71 | (266) | (255) |
| Repayment of interest on long-term liabilities | 71 | (751) | (581) |
| Net cash from financing activities | 34 | (12,361) | |
| Total net cash flows | (667) | 11,220 | |
| of which foreign exchange differences on cash and cash equivalents | (872) | 100 | |
| Cash and cash equivalents at the beginning of the period | 31,995 | 20,775 | |
| Cash and cash equivalents at the end of the period | 71 | 31,328 | 31,995 |
* The Statement of cash flows for 2022 was restated due to the implementation of IFRS 17 “Insurance Contracts” (see note “IFRS 17 Insurance Contracts”).